A Study of Two Formulations of Ixekizumab in Healthy Participants
Status:
Completed
Trial end date:
2021-02-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare two different formulations of ixekizumab. One
formulation (Reference) is approved by the Food and Drug Administration (FDA) and one
formulation (Test) is not approved. This study will compare how much of each formulation gets
into the blood stream. Information about any side effects that may occur will also be
collected. The study will last up to about four months for each participant.